Grotsch Katharina, Fokin Valery V
Bridge Institute and Loker Hydrocarbon Research Institute, University of Southern California, 1002 Childs Way, Los Angeles, California 90089-3502, United States.
ACS Cent Sci. 2022 Feb 23;8(2):156-168. doi: 10.1021/acscentsci.1c01100. Epub 2022 Jan 26.
At the intersection of science and medicine, government policy, and pop culture, cannabis has prompted society since the beginning of recorded history. And yet, there is comparatively little replicable data on the plant, its constituents, and their capacity to modify human physiology. Over the past decades, several findings have pointed toward the importance of the endogenous cannabinoid system in maintaining homeostasis, making it an important target for various diseases. Here, we summarize the current state of knowledge on endogenous- and plant-based cannabinoids, address the issues related to cannabinoid-based drug discovery, and incite efforts to utilize their polypharmacological profile toward tackling diseases with a complex underlying pathophysiology. By fusing modern science and technology with the empirical data that has been gathered over centuries, we propose an outlook that could help us overcome the dearth of innovation for new drugs and synchronously redefine the future of drug discovery. Simultaneously, we call attention to the startling disconnect between the scientific, regulatory, and corporate entities that is becoming increasingly evident in this booming industry.
在科学与医学、政府政策及流行文化的交叉领域，大麻自历史有记载之初便引发了社会关注。然而，关于这种植物、其成分以及它们改变人体生理机能能力的可重复数据相对较少。在过去几十年里，多项研究结果表明内源性大麻素系统在维持体内平衡方面的重要性，使其成为各种疾病的重要靶点。在此，我们总结了关于内源性和植物源性大麻素的当前知识状况，探讨了基于大麻素的药物研发相关问题，并鼓励利用它们的多药理学特性来应对具有复杂潜在病理生理学的疾病。通过将现代科学技术与数百年来收集的经验数据相结合，我们提出一种展望，有望帮助我们克服新药创新的匮乏，并同步重新定义药物研发的未来。同时，我们提请注意在这个蓬勃发展的行业中，科学、监管和企业实体之间惊人的脱节正日益明显。
